Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FGFR2 rearrangements status confers therapeutic sensitivity to Pemigatinib in patients with Cholangiocarcinoma.
Health Canada approved pemigatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
This statement is based on a regulatory approval from the Health Canada:
PEMAZYRE (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.